 A chemotherapy combined with an anti-angiogenic drug applied to a cancer model including angiogenesisChristophe Letellier, Sourav Kumar Sasmal, Clément Draghi, Fabrice Denis and Dibakar Ghosh Chaos, Solitons & Fractals, 2017, vol. 99, issue C, 297-311 Abstract: Combined therapy made of a chemotherapy and antiangiogenic agents is a clinical treatment recommended for its efficiency. Since the optimization of a treatment against cancer relasp is still mostly based on oncologist’s know-how, it is desirable to develop different approaches for such a task. Mathematical modelling is one of the promising ways. We here investigated the action of a combined therapy inserted to a mathematical cancer model in order to determine how the dynamics underlying tumor growth is governed by some key parameters. We here retained a chemotherapy (for instance, paclitaxel and carboplatin) combined with an antiangiogenic drug (as bevacizumab) applied to a cancer model describing the interactions between host, immune, tumor and endothelial cells. The effects of such a therapy are investigated and the relevant role played by the “normal” tissue of the tumor micro-environment is evidenced. Keywords: Chemotherapy; Anti-angiogenic drug; Tumor cells; Endothelial cells; Tumor micro-environment (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:eee:chsofr:v:99:y:2017:i:c:p:297-311 DOI: 10.1016/j.chaos.2017.04.013 Access Statistics for this article Chaos, Solitons & Fractals is currently edited by Stefano Boccaletti and Stelios Bekiros More articles in Chaos, Solitons & Fractals from Elsevier |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.